ArticleAngewandte Chemie (International ed. in English)2025
Thiotemplated Polyketide Chain Fusion and Reductive Cyclization Build the Reactive Butenolide Core of Malleicyprol.
Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Photoreactive Pantetheinyl Mimics Reveal Design Limitations for Crypto-Acyl Carrier Proteins.Chembiochem : a European journal of chemical biology · 2026Article
- Inactivation of the Burkholderia Toxin Malleicyprol by Enzymatic Cyclopropanol Ring Opening.Angewandte Chemie (International ed. in English) · 2026Article
- Reaction Engineering of In Vitro Natural Product Biosynthesis: Challenges and Strategies.Chembiochem : a European journal of chemical biology · 2025Review
- Thiotemplated Polyketide Chain Fusion and Reductive Cyclization Build the Reactive Butenolide Core of Malleicyprol.Angewandte Chemie (International ed. in English) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Malleicyprol, a virulence factor of notorious animal and human pathogens of the Burkholderia pseudomallei (BP) group, features a molecular cyclopropanol warhead linked to a reactive butenolide core. Biosynthetic considerations suggested that this heterocycle was formed by the merger of two individual polyketide chains, but the precise mechanism has remained elusive. By combining chemical synthesis, complete in vitro reconstitution of the biotransformation, and mutational analysis, we show that two individually generated polyketide chains are joined by a noncanonical condensation domain of the PKS-NRPS hybrid synthetase BurF, which forms an ester bond. By mutagenesis, biochemical assays, and trapping of the aldehyde generated from a substrate surrogate, we found that the terminal reductase domain mediates a reductive chain release with concomitant ring formation. The feasibility of the proposed Knoevenagel-type intramolecular cyclization into the butenolide moiety was confirmed by a biomimetic synthesis of malleicyprol. The elucidation of the unprecedented thiotemplated butenolide biosynthesis by head-to-head fusion of two polyketide chains not only expands the synthetic biology toolbox but may also inspire the development of antivirulence strategies against BP pathogen infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.